Endoluten: A Six-Module Literature Course

Endoluten is a brand name associated with the Khavinson family of "peptide bioregulators": preparations whose product descriptions present them as polypeptide complexes obtained from animal organ tissue, in this case the pineal gland (epiphysis). Understanding the literature around it requires one distinction up front. None of the verified, PubMed-indexed papers summarised below studied a commercial product sold under the Endoluten brand name. What the indexed record contains instead is research on pineal peptide preparations generally (published mainly as Epithalamin), on a registered pineal polypeptide drug (Pineamin), and on the synthetic tetrapeptide AEDG, often written as Epitalon.

This six-module course summarises what the published record actually contains, what it does not contain, and where the boundary between the two falls. Every dose, endpoint or outcome statement is tied to a cited paper in the same sentence, and effects that the cited abstracts do not describe are left out rather than paraphrased. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or decision.

Module 1 — What Endoluten Is and How It Has Been Studied

In product literature, Endoluten is described as an oral (capsule) preparation of a pineal gland polypeptide complex, positioned within the same family as injectable pineal peptide preparations developed in Russian gerontology research. The scientific bridge between a branded pineal complex and the better-studied synthetic peptide comes from an analytical paper: researchers reported the identification of the tetrapeptide AEDG (Ala-Glu-Asp-Gly) within a polypeptide complex of the pineal gland, describing it as a constituent of that complex (PMID 29124531).

The class context is also published. A review of pineal gland aging described age-related structural and functional changes in the gland as the rationale researchers used for testing pineal peptide preparations in gerontology (PMID 12096440). An older experimental report framed peptide preparations of this type as acting in a tissue-specific manner, which is the conceptual basis of the "bioregulator" label used for these products (PMID 11713572).

Study formats in the verified set fall into a small number of shapes:

• Animal experiments in rodents and in monkeys, including a report on peptide correction of age-related pineal disturbances in monkeys (PMID 14743609).
• Cell and molecular work, including a study reporting that AEDG peptide stimulated gene expression and protein synthesis during neurogenesis (PMID 32019204).
• Human work on a registered pineal preparation, reported for elderly participants (PMID 28849889).
• Narrative reviews, such as a review of genetic and epigenetic factors in skin fibroblast aging (PMID 32160428).

Limits of the evidence in Module 1

The brand name itself is absent from the verified literature, so nothing here establishes that a capsule product and an injected or applied pineal peptide preparation behave alike. The identification of AEDG inside a pineal complex (PMID 29124531) shows a shared constituent, not equivalence of composition, purity, quantity or route. Much of the work is published in Russian-language gerontology journals with brief English abstracts, which restricts what can be verified about methods.

Module 2 — Mechanism as Described in the Literature

Three mechanistic themes recur across the verified papers.

Melatonin and pineal function

The clearest human mechanistic claim is hormonal: a report on the pineal preparation Pineamin stated in its title and abstract that it increased pineal melatonin synthesis in elderly people (PMID 28849889). In non-human primates, researchers reported that peptide treatment was used to correct age-related disturbances of pineal function (PMID 14743609). A review positioned these efforts against documented age-related decline in pineal function (PMID 12096440).

Free-radical and antioxidant processes

A second theme is redox biology. One paper reported effects of the pineal peptide preparation Epithalamin on free-radical processes in both humans and animals (PMID 11335874). A later paper described antioxidant properties of geroprotective peptides of the pineal gland (PMID 17317455).

Gene expression and epigenetics

The third theme is transcriptional. The study of AEDG peptide reported stimulation of gene expression and protein synthesis during neurogenesis and proposed an epigenetic mechanism for that observation (PMID 32019204). A related review discussed genetic and epigenetic factors in the aging of skin fibroblasts as the framework in which short peptides have been investigated (PMID 32160428). Tissue-specific peptide action was described earlier as a general property of such preparations (PMID 11713572).

Limits of the evidence in Module 2

These mechanisms are described, not demonstrated end-to-end. No verified paper connected an oral pineal capsule to a measured melatonin change in humans, and the melatonin report concerns a specific registered injectable preparation (PMID 28849889). The epigenetic mechanism was explicitly framed as possible rather than established (PMID 32019204). Antioxidant findings (PMID 17317455) describe biochemical properties, not clinical consequences.

Module 3 — Reported Outcomes, Study by Study

The table below lists what each verified paper examined and what its authors reported. It is a map of the literature, not a summary of expected results in any individual.

Two features of this outcome set are worth naming. First, the endpoints are mostly biomarkers and physiological measures — melatonin synthesis, redox chemistry, cytogenetic counts, enzyme activity, functional rhythms — rather than patient-centred outcomes such as disease incidence, symptom scores or survival. Second, the human data in the verified set is confined to a melatonin-synthesis report in elderly people (PMID 28849889) and the human component of the free-radical work (PMID 11335874).

Limits of the evidence in Module 3

Nothing in this module should be read as a benefit of a consumer product. The animal studies used specific models — senescence-accelerated mice (PMID 12360351), aging rodents under controlled lighting (PMID 26519279), aging monkeys (PMID 14743609) — that do not translate automatically to humans. Sample sizes, blinding, randomisation and replication status are not verifiable from the indexed abstracts, and no independent multi-centre replication appears in this verified set.

Module 4 — Endoluten Side Effects: What Studies Report

Safety reporting is the thinnest part of this literature, and that thinness is itself the finding. Across the verified set, the indexed abstracts are organised around efficacy-type endpoints and do not present structured adverse-event tables, withdrawal counts or laboratory-safety panels.

• The human report on the pineal preparation Pineamin in elderly people was framed around increased pineal melatonin synthesis and did not, in its indexed abstract, describe adverse events, tolerability grading or discontinuations (PMID 28849889).
• The report on Epithalamin and free-radical processes in humans and animals likewise centred on biochemical endpoints without an indexed adverse-event summary (PMID 11335874).
• The monkey study on age-related pineal disturbances reported physiological correction as its endpoint and did not present a toxicology or adverse-event section in its abstract (PMID 14743609).
• The cytogenetic study in senescence-accelerated mice used chromosome aberration incidence as its measured endpoint rather than clinical tolerability (PMID 12360351).

Because of this, no verified paper in the set supports a statement that a pineal peptide preparation was free of side effects, nor a list of typical side effects with frequencies. Absence of reported adverse events in an abstract is not evidence of safety; it usually means adverse events were not a reported endpoint or were not captured in the indexed summary.

Limits of the evidence in Module 4

There is no long-term human safety dataset in the verified set, no pregnancy or paediatric safety data, no drug-interaction study, and no immunogenicity assessment for an animal-tissue-derived complex. Because AEDG was reported as a constituent of the pineal polypeptide complex (PMID 29124531), safety observations about one form cannot be assumed to apply to another form, route or manufacturing process. Anyone weighing risk needs a licensed clinician, not an abstract.

Module 5 — Pharmacokinetics, Where Data Exist

Within the verified set, pharmacokinetic data are effectively absent. No paper listed here reported plasma concentration–time curves, bioavailability, half-life, volume of distribution, metabolic pathways, clearance or excretion routes for a pineal polypeptide complex or for AEDG.

What the literature offers instead is indirect. The analytical identification of AEDG inside a pineal polypeptide complex established a defined short peptide within a mixture, which is the kind of characterisation that pharmacokinetic work would normally build on (PMID 29124531). The neurogenesis study reported gene-expression and protein-synthesis responses to AEDG peptide, implying tissue-level exposure in that experimental system without quantifying systemic kinetics (PMID 32019204). The older tissue-specificity report described differential peptide action across tissues, a distribution-related idea rather than a kinetic measurement (PMID 11713572).

Limits of the evidence in Module 5

Route matters most here and is least documented. An oral polypeptide preparation faces gastric and intestinal proteolysis, and one verified paper is a reminder that proteolytic enzyme activity itself changes with age and lighting conditions in animals (PMID 26519279). No verified paper measured how much intact peptide from an oral pineal complex reaches circulation in humans, so oral exposure remains unquantified in this evidence base.

Module 6 — Regulatory Status, Stated Factually

The regulatory picture differs by product and by country, and the distinctions are worth stating plainly.

• Registered pharmaceutical. Pineamin is a pineal polypeptide product that has been studied and published as a registered preparation in Russia, where the human melatonin-synthesis report was conducted in elderly people (PMID 28849889). Registration in one country does not confer approval elsewhere.
• United States. The US Food and Drug Administration has not approved any pineal peptide bioregulator, Epithalamin preparation, or AEDG/Epitalon product as a drug for any indication. Synthetic AEDG sold by chemical suppliers is typically labelled research use only (RUO), meaning it is not intended for human or veterinary use and is not manufactured to pharmaceutical standards.
• Supplement framing. Branded bioregulator capsules, including products marketed under the Endoluten name, are generally presented outside the US as dietary or food supplements rather than as approved medicines, which means they are not reviewed for efficacy in the way drugs are.
• Compounding. In the United States, compounding pharmacies may prepare drugs from bulk substances only under the statutory categories set out for sections 503A and 503B facilities; a substance must fall within those permitted categories, and an animal-tissue-derived organ complex or an unapproved synthetic peptide does not become an approved drug by being compounded.

This is general information about regulatory categories, not legal advice; rules change and differ by jurisdiction, and questions about a specific product or country should go to a qualified professional.

Limits of the evidence in Module 6

Regulatory status is independent of biological interest. A registered preparation with a published human melatonin finding (PMID 28849889) and a research-grade synthetic peptide studied in a neurogenesis model (PMID 32019204) occupy entirely different legal and quality categories even when they share a peptide sequence (PMID 29124531).

What the Studies Did Not Test

The most useful summary of this evidence base is a list of the questions it left open:

1. The branded product. No verified paper tested a product sold under the Endoluten name, or compared an oral capsule with an injectable pineal preparation.
2. Hard clinical outcomes. The verified endpoints are biomarkers and physiological measures — melatonin synthesis (PMID 28849889), free-radical processes (PMID 11335874), chromosome aberration counts (PMID 12360351) — not disease incidence, function or mortality in humans.
3. Dose–response in humans. The indexed abstracts in this set do not establish a human dose–response relationship, so no schedule is described on this page.
4. Safety over time. No long-term human safety follow-up, interaction study or immunogenicity assessment appears in the verified set (PMID 14743609).
5. Healthy young populations. The work is framed around aging models and elderly participants (PMID 12096440), and the fibroblast aging framework is a review rather than an intervention trial (PMID 32160428).
6. Independent replication. The verified reports cluster in a small literature; large independent replications of the thymus and bone marrow rhythm findings (PMID 15490729) or the antioxidant characterisation (PMID 17317455) are not present here.

Read as a whole, the record is a set of early-stage biological observations, mostly preclinical, mostly single-group, with one human melatonin-synthesis report attached to a specific registered preparation. That is a fair description of where the science stands, and it is different from a demonstrated clinical effect.

References

• Identification of Peptide AEDG in the Polypeptide Complex of the Pineal Gland (Bulletin of Experimental Biology and Medicine, 2017)
• AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism (Molecules, 2020)
• Pineamin increased pineal melatonin synthesis in elderly people (Advances in Gerontology, 2017)
• Effects of pineal peptide preparation Epithalamin on free-radical processes in humans and animals (Neuroendocrinology Letters, 2001)
• Antioxidant properties of geroprotective peptides of the pineal gland (Archives of Gerontology and Geriatrics, 2007)
• Effect of epithalon on the incidence of chromosome aberrations in senescence-accelerated mice (Bulletin of Experimental Biology and Medicine, 2002)
• The pineal gland's peptides factors and the rhythms of functions of the thymus and bone marrow in animals during aging (Advances in Gerontology, 2004)
• Peptide correction of age-related pineal disturbances in monkeys (Advances in Gerontology, 2003)
• Aging of the pineal gland (Advances in Gerontology, 2002)
• Effects of Geroprotectors on Age-Related Changes in Proteolytic Digestive Enzyme Activities at Different Lighting Conditions (Bulletin of Experimental Biology and Medicine, 2015)
• Tissue-specific effects of peptides (Bulletin of Experimental Biology and Medicine, 2001)
• Aging of skin fibroblasts: genetic and epigenetic factors (Advances in Gerontology, 2019)